钠-葡萄糖共转运蛋白 2 抑制剂与心血管结局：它们有差异还是存在类效应？来自 EMPA-REG OUTCOME 试验和 CVD-REAL 研究的新见解。
SGLT2 Inhibitors and Cardiovascular Outcomes: Do they Differ or there is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study.
机构信息
Seccion de Endocrinologia y Nutrition, Hospital General Universitario Santa Lucia, Cartagena, Spain.
Centro de Salud Jesús Marín, Murcia, Spain.
出版信息
Curr Cardiol Rev. 2020;16(4):258-265. doi: 10.2174/1573403X15666190730094215.
A new group of hypoglycemic drugs has been used to treat diabetes type 2. This group is active sodium glucose co-transporter (SGLT2) or SGLT2 inhibitors. It has been shown that besides the treatment of diabetes, this drug class is responsible for the mildness of the cardiovascular events shown in patients with diabetes type 2. However, there is an intriguing question regarding the range of SGLT2 inhibitors and if there is a difference between them or if there is a class effect among their results. EMPA-REG OUTCOME trial and the CVD-study are used to answer this question. Additional information from the DECLARE-TIMI 58 and Dapa-HF trials is studied.
一组新的降血糖药物已被用于治疗 2 型糖尿病。该组药物为活性钠-葡萄糖协同转运蛋白（SGLT2）或 SGLT2 抑制剂。研究表明，除了治疗糖尿病外，这类药物还可降低 2 型糖尿病患者心血管事件的严重程度。然而，关于 SGLT2 抑制剂的范围存在一个有趣的问题，即它们之间是否存在差异，或者它们的结果是否存在类效应。EMPA-REG OUTCOME 试验和 CVD 研究被用来回答这个问题。DECLARE-TIMI 58 试验和 Dapa-HF 试验的其他信息也被研究。
Zotero 插件